CSBR — Champions Oncology Income Statement
0.000.00%
- $68.58m
- $64.11m
- $53.87m
- 60
- 49
- 78
- 66
Annual income statement for Champions Oncology, fiscal year end - April 30th, USD millions except per share, conversion factor applied.
2019 April 30th | 2020 April 30th | 2021 April 30th | 2022 April 30th | 2023 April 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 27.1 | 32.1 | 41 | 49.1 | 53.9 |
Cost of Revenue | |||||
Gross Profit | 12.8 | 15.2 | 19.6 | 25.5 | 24.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 26.8 | 33.9 | 40.7 | 48.5 | 59.1 |
Operating Profit | 0.27 | -1.8 | 0.366 | 0.607 | -5.26 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.231 | -1.84 | 0.437 | 0.583 | -5.27 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.128 | -1.98 | 0.362 | 0.548 | -5.33 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.128 | -1.98 | 0.362 | 0.548 | -5.33 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.128 | -1.98 | 0.362 | 0.548 | -5.33 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.009 | -0.148 | 0.021 | 0.034 | -0.355 |